Complications After Myocardial Infarction

Thompson, Peter L.; McKeown, B.

doi:10.1002/9780470986882.ch35

Cited by 3 publications

(3 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two major textbooks on evidence‐based cardiology also conclude that cardiac rehabilitation is highly effective in preventing mortality 2 , 5 . So, should we question these compelling data?…”

Section: Misleading Presentation Of Resultsmentioning

confidence: 99%

“…It is apparent that the authors believe that the condition is both benign and rare. The article states that “VF occurring in the absence of cardiogenic shock, severe heart failure or hypotension (primary VF) has a good short‐term prognosis”! 5 It also stated that the frequency of VF was 5% to 10% in the 1970s, but dropped to <2% in the 1980s.…”

Section: Clinical Situations Unsuitable For Randomized Trialsmentioning

confidence: 99%

See 1 more Smart Citation

What is Right and What is Wrong About Evidence‐Based Medicine?

Julian

2003

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Practice should, as much as possible, be based on good science. Randomized clinical trials can provide the best evidence, but they have serious limitations. First, many clinical situations, such as cardiac arrest and pain relief, do not lend themselves to randomization. Second, trials seldom can study the effects seen in different subgroups, nor can the results always be extrapolated from the restricted groups of patients recruited into trials. Finally, there is publication bias: the failure to report "negative" trials and the biased presentation of results by investigators and sponsors.

show abstract

Section: Misleading Presentation Of Resultsmentioning

confidence: 99%

Section: Clinical Situations Unsuitable For Randomized Trialsmentioning

confidence: 99%

What is Right and What is Wrong About Evidence‐Based Medicine?

Julian

2003

Cardiovasc electrophysiol

View full text Add to dashboard Cite

show abstract

“…Cardiovascular diseases (CVDs) are the leading cause of total deaths worldwide, accounting for 31% of total mortality in 2015 with an estimated 17.7 million deaths, of which 7.4 million people died from coronary heart disease in particular [1]. The global burden of ischemic heart disease is experiencing a growing trend from 47 million in 1990 to 82 million disability-adjusted life-years in 2020 [2]. The patients with CVDs die mostly because of myocardial infarction (MI) (or so-called heart attack).…”

Section: Introductionmentioning

confidence: 99%

Fabrication and characterization of carbon aerogel/poly(glycerol-sebacate) patches for cardiac tissue engineering

Atya¹,

Tevlek²,

Almemar³

et al. 2021

Biomed. Mater.

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are responsible for the major number of deaths around the world. Among these is heart failure after myocardial infarction whose latest therapeutic methods are limited to slowing the end-state progression. Numerous strategies have been developed to meet the increased demand for therapies regarding CVDs. This study aimed to establish a novel electrically conductive elastomer-based composite and assess its potential as a cardiac patch for myocardial tissue engineering. The electrically conductive carbon aerogels (CAs) used in this study were derived from waste paper as a cost-effective carbon source and they were combined with the biodegradable poly(glycerol-sebacate) (PGS) elastomer to obtain an electrically conductive cardiac patch material. To the best of our knowledge, this is the first report about the conductive composites obtained by the incorporation of CAs into PGS (CA-PGS). In this context, the incorporation of the CAs into the polymeric matrix significantly improved the elastic modulus (from 0.912 MPa for the pure PGS elastomer to 0.366 MPa for the CA-PGS) and the deformability (from 0.792 MPa for the pure PGS to 0.566 MPa for CA-PGS). Overall, the mechanical properties of the obtained structures were observed similar to the native myocardium. Furthermore, the addition of CAs made the obtained structures electrically conductive with a conductivity value of 65 × 10−3 S m−1 which falls within the range previously recorded for human myocardium. The in vitro cytotoxicity assay with L929 murine fibroblast cells revealed that the CA-PGS composite did not have cytotoxic characteristics. On the other hand, the studies conducted with H9C2 rat cardiac myoblasts revealed that final structures were suitable for MTE applications according to the successes in cell adhesion, cell proliferation, and cell behavior.

show abstract